- Home
- RPTX vs EDAP Comparison
RPTX vs EDAP Comparison
Compare RPTX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- EDAP
- Stock Information
- Founded
- RPTX 2016
- EDAP 1979
- Country
- RPTX Canada
- EDAP France
- Employees
- RPTX N/A
- EDAP N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RPTX Health Care
- EDAP Health Care
- Exchange
- RPTX Nasdaq
- EDAP Nasdaq
- Market Cap
- RPTX 63.9M
- EDAP 53.8M
- IPO Year
- RPTX 2020
- EDAP 1997
- Fundamental
- Price
- RPTX $1.54
- EDAP $1.51
- Analyst Decision
- RPTX Strong Buy
- EDAP Buy
- Analyst Count
- RPTX 3
- EDAP 3
- Target Price
- RPTX $4.50
- EDAP $8.50
- AVG Volume (30 Days)
- RPTX 95.0K
- EDAP 36.8K
- Earning Date
- RPTX 08-05-2025
- EDAP 08-27-2025
- Dividend Yield
- RPTX N/A
- EDAP N/A
- EPS Growth
- RPTX N/A
- EDAP N/A
- EPS
- RPTX N/A
- EDAP N/A
- Revenue
- RPTX $1,073,000.00
- EDAP $67,840,467.00
- Revenue This Year
- RPTX N/A
- EDAP N/A
- Revenue Next Year
- RPTX N/A
- EDAP N/A
- P/E Ratio
- RPTX N/A
- EDAP N/A
- Revenue Growth
- RPTX N/A
- EDAP 3.69
- 52 Week Low
- RPTX $0.89
- EDAP $1.26
- 52 Week High
- RPTX $4.29
- EDAP $5.27
- Technical
- Relative Strength Index (RSI)
- RPTX 65.29
- EDAP 34.23
- Support Level
- RPTX $1.40
- EDAP $1.51
- Resistance Level
- RPTX $1.59
- EDAP $1.63
- Average True Range (ATR)
- RPTX 0.05
- EDAP 0.10
- MACD
- RPTX 0.01
- EDAP -0.01
- Stochastic Oscillator
- RPTX 81.82
- EDAP 3.33
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.